Search Results - "TAKIGUCHI, Y."

Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary by Tanizaki, J., Yonemori, K., Akiyoshi, K., Minami, H., Ueda, H., Takiguchi, Y., Miura, Y., Segawa, Y., Takahashi, S., Iwamoto, Y., Kidera, Y., Fukuoka, K., Ito, A., Chiba, Y., Sakai, K., Nishio, K., Nakagawa, K., Hayashi, H.

“…Cancer of unknown primary (CUP) has a poor prognosis. Given the recent approval of immune checkpoint inhibitors for several cancer types, we carried out a…”
Get full text

MicroRNA-125b regulates proliferation and radioresistance of oral squamous cell carcinoma by Shiiba, M, Shinozuka, K, Saito, K, Fushimi, K, Kasamatsu, A, Ogawara, K, Uzawa, K, Ito, H, Takiguchi, Y, Tanzawa, H

“…Background: MicroRNAs (miRNAs) are involved in essential biological activities, and have been reported to exhibit differential expression profiles in various…”
Get full text

Urinary titin as a biomarker of sarcopenia in diabetes: a propensity score matching analysis by Takiguchi, Y., Tsutsumi, R., Shimabukuro, M., Tanabe, H., Kawakami, A., Hyodo, M., Shiroma, K., Saito, H., Matsuo, M., Sakaue, H.

“…Measuring urinary titin levels is expected to be useful in screening for muscle damage or injury in various diseases. We evaluated whether urinary titin levels…”
Get full text

A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial by Kubota, K., Sakai, H., Katakami, N., Nishio, M., Inoue, A., Okamoto, H., Isobe, H., Kunitoh, H., Takiguchi, Y., Kobayashi, K., Nakamura, Y., Ohmatsu, H., Sugawara, S., Minato, K., Fukuda, M., Yokoyama, A., Takeuchi, M., Michimae, H., Gemma, A., Kudoh, S.

“…Platinum-based two-drug combination chemotherapy has been standard of care for patients with advanced nonsmall-cell lung cancer (NSCLC). The primary aim was to…”
Get full text

Direct evidence for three-dimensional off-axis trapping with single Laguerre-Gaussian beam by Otsu, T., Ando, T., Takiguchi, Y., Ohtake, Y., Toyoda, H., Itoh, H.

“…Optical tweezers are often applied to control the dynamics of objects by scanning light. However, there is a limitation that objects fail to track the scan…”
Get full text

Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer by Hotta, K., Hida, T., Nokihara, H., Morise, M., Kim, Y.H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Kumagai, T., Watanabe, S., Goto, K., Satouchi, M., Kozuki, T., Shukuya, T., Nakagawa, K., Mitsudomi, T., Yamamoto, N., Asakawa, T., Yoshimoto, T., Takata, S., Tamura, T.

“…Mature progression-free survival (PFS) data from the phase III J-ALEX study showed superiority for alectinib versus crizotinib [hazard ratio (HR) 0.37, 95%…”
Get full text

Survival update in randomized phase II trial of S-1/cisplatin (SP) or docetaxel/cisplatin (DP) with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer (NSCLC)-TORG1018 by Takiguchi, Y., Yamada, K., Tanaka, H., Kubota, K., Kishi, K., Shimokawa, T., Saito, H., Hosomi, Y., Kato, T., Nogami, N., Igawa, S., Kasai, T., Nakamura, Y., Yamanaka, T., Okamoto, H.

Get full text

Megabits secure key rate quantum key distribution by Zhang, Q, Takesue, H, Honjo, T, Wen, K, Hirohata, T, Suyama, M, Takiguchi, Y, Kamada, H, Tokura, Y, Tadanaga, O, Nishida, Y, Asobe, M, Yamamoto, Y

Get full text

Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM by Watanabe, S., Yoshioka, H., Sakai, H., Hotta, K., Takenoyama, M., Yamada, K., Sugawara, S., Takiguchi, Y., Hosomi, Y., Tomii, K., Niho, S., Nishio, M., Kato, T., Takahashi, T., Ebi, H., Aono, M., Yamamoto, N., Ohe, Y., Nakagawa, K.

“…Efficacy of necitumumab [recombinant human monoclonal antibody that blocks the ligand binding epidermal growth factor receptor (EGFR)] in patients with…”
Get full text

Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions by Okamoto, S, Jiang, Y, Kawamura, K, Shingyoji, M, Tada, Y, Sekine, I, Takiguchi, Y, Tatsumi, K, Kobayashi, H, Shimada, H, Hiroshima, K, Tagawa, M

“…Zoledronic acid (ZOL), a nitrogen-containing bisphosphonate, produced anti-tumor effects through apoptosis induction or S-phase arrest depending on human…”
Get full text

Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed by Li, Q, Kawamura, K, Yamanaka, M, Okamoto, S, Yang, S, Yamauchi, S, Fukamachi, T, Kobayashi, H, Tada, Y, Takiguchi, Y, Tatsumi, K, Shimada, H, Hiroshima, K, Tagawa, M

“…The majority of malignant mesothelioma possesses the wild-type p53 gene with a homologous deletion of the INK4A/ARF locus containing the p14 ARF and the p16…”
Get full text

3064 NEJ016: Phase II study of carboplatin and weekly paclitaxel plus bevacizumab followed by bevacizumab for highly selected elderly non-squamous non-small cell lung cancer patients by Harada, T, Miura, S, Maemondo, M, Iwashima, A, Sugawara, S, Kobayashi, K, Inoue, A, Nakagawa, T, Takiguchi, Y, Watanabe, H, Seike, M, Ishida, T, Terada, M, Gemma, A, Yoshizawa, H

Get full text

Experimental observation of complete chaos synchronization in semiconductor lasers by Liu, Y., Takiguchi, Y., Davis, P., Aida, T., Saito, S., Liu, J. M.

“…We experimentally demonstrate the complete synchronization of a semiconductor laser to the injection of a chaotic oscillating optical signal that is generated…”
Get full text

Incidence, risk factors and treatment outcomes of extravasation of cytotoxic agents in an outpatient chemotherapy clinic by Sakaida, Emiko, Sekine, Ikuo, Iwasawa, Shunichiro, Kurimoto, Ryota, Uehara, Takashi, Ooka, Yoshihiko, Akanuma, Naoki, Tada, Yuji, Imai, Chiaki, Oku, Tomoko, Takiguchi, Yuichi

“…Extravasation, the accidental leakage of an anticancer agent from a vessel into the surrounding tissues, can lead to irreversible local injuries and severe…”
Get full text

3072 Phase 2: Docetaxel with or without ramucirumab as therapy for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations after prior EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy by Kasahara, K, Kiura, K, Nogami, N, Takayama, K, Takiguchi, Y, Hirashima, T, Aoe, K, Hayashi, H, Saka, H, Takahashi, K, Imamura, F, Oizumi, S, Inoue, A, Satouchi, M, Tatsumi, M, Nakamura, T, Enatsu, S, Tamura, T, Nakagawa, K

Get full text

89 Targeting nuclear factor-kappa B in malignant pleural mesothelioma by Gately, K, Jennions, E, Godwin, P, Barr, M.P, Heavey, S, Takiguchi, Y, Umezawa, K, Edwards, J.G, Gray, S.G

Get full text

Feasibility of cytological diagnosis of sarcoidosis with endobronchial US-guided transbronchial aspiration by Kitamura, A, Takiguchi, Y, Kurosu, K, Takigawa, N, Saegusa, F, Hiroshima, K, Nakajima, T, Tanabe, N, Nakatani, Y, Yoshino, I, Tatsumi, K

“…Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has a high diagnostic value in sarcoidosis if the obtained histological specimen…”
Get full text

Hiccups as an Adverse Reaction to Cancer Chemotherapy by Takiguchi, Yuichi, Watanabe, Reiko, Nagao, Keiichi, Kuriyama, Takayuki

“…Vinorelbine 10/1066 10/630 0/436 19882001Total (%) 162/41 215 (0.39%) 157/22 503 (0.70%) 5/18 712 (0.03%) 19792001*The incidence of hiccups was statistically…”
Get full text

83 HDAC expression levels may play a role in cisplatin resistant MPM by Baird, A.M, Jennings, C.J, Flynn, L, O'Donnell, E, Barr, M.P, Santoni-Rugiu, E, Takiguchi, Y, Thomas, W, Zimling, Z.G, O'Byrne, K.J, Gray, S.G

Get full text

Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer by WATANABE, R, TAKIGUCHI, Y, MORIYA, T, ODA, S, KUROSU, K, TANABE, N, TATSUMI, K, NAGAO, K, KURIYAMA, T

“…Cancer chemotherapy for haemodialysis patients has never been established. To elucidate the feasibility of cisplatin-based combination chemotherapy for…”
Get full text